Navigation Links
Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th

AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website,, on November 10th, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF."

About Merriman Curhan Ford

Merriman Curhan Ford (Nasdaq: MERR) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech, Consumer, Media & Internet, Health Care, Natural Resources and Technology. For more information, please go to

    For further information contact:
    Investor Relations
    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel: (212) 845-4226

    Media Relations
    Ian Stone
    Russo Partners LLC
    Tel: (619) 814-3510
    Fax: (619) 955-5318

This News Release contains certain forward-looking statements and information (collectively, "forward-looking statements") regarding the Company's planned presentation at Merriman Curhan Ford's 6th annual Investor Summit and the Company's research and development initiatives, which statements can be identified by the use of forward looking terminology such as "will", "developing", "November 10, 2009", or comparable forward-looking terminology. Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, the fact that the presentation and the posting of the slide show portion of the presentation on the Company's website are subject to change or cancellation without notice; Helix's need for additional future capital, which may not be available in a timely manner or at all; the need for additional research and development, the outcome of which is uncertain; and uncertainty whether L-DOS47 or Topical Interferon Alpha-2b, or any other product development initiatives, will be successfully developed or commercialized. See the Company's latest Form 20-F and other reports filed from time to time on SEDAR at, and on EDGAR at for a further description of certain of these and other important risks and uncertainties affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements. The Company does not assume any obligation to update any forward-looking statement except as required by law. The Company has relied solely on Merriman Curhan Ford for the information about them provided in this News Release and the Company disclaims any liability with respect to such information or with respect to information contained in their website, which is referenced for convenience only and not as an endorsement by Helix of such website.

SOURCE Helix BioPharma Corp.

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
2. Helix BioPharma Closes Private Placement
3. Helix BioPharma Announces $13.5 Million Private Placement
4. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
6. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
7. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
8. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
9. Helix BioPharma to Present at the BioFinance 2009 Conference
10. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
11. Helix BioPharma Announces Q2 2009 Financial Results
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015 Orexigen® ... management will participate in a fireside chat discussion at ... New York . The discussion is scheduled ... .  A replay will be ... Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association ... 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award ... work with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
Breaking Biology Technology:
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
Breaking Biology News(10 mins):